|Systematic (IUPAC) name|
|Pregnancy cat.||C (US)|
|Protein binding||76% (trovafloxacin)|
|Metabolism||Quickly hydrolyzed to trovafloxacin|
|Half-life||9 to 12 hours (trovafloxacin)|
|Excretion||Fecal and renal (trovafloxacin)|
|Mol. mass||558.509 g/mol|
|(what is this?)|
Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 that encountered criticism for its Nigerian trials and adverse clinical reactions.
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.
- "PubChem CID 5489474".
- Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. doi:10.1016/S0753-3322(03)00054-4. PMID 14568230.
- Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMC 1471980. PMID 16735322.
|This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.|